Zerbaxa should be added to the ACPHS forulary and Zosyn should remain on the formulary. Both drugs are used to treat bacterial infections in several parts of the body. While the current formulary drug Zosyn has many more uses than the formulary candidate Zerbaxa, the latter still has some uses that are not covered by Zosyn such as pyelonephritis.2 Zerbaxa is available in fewer dosage forms but this should not be an issue since is normally only dosed 1.5 g at a time.4 The current drug Zosyn has many more warning criteria than Zerbaxa which means there is more monitoring involved with Zosyn. Zosyn also has many more adverse effects than Zerbaxa and many of these effects are much more severe than those associated with Zerbaxa treatment.3
